254 related articles for article (PubMed ID: 36558921)
1. Cyclooxygenase-2 (COX-2) as a Target of Anticancer Agents: A Review of Novel Synthesized Scaffolds Having Anticancer and COX-2 Inhibitory Potentialities.
Mohsin NUA; Aslam S; Ahmad M; Irfan M; Al-Hussain SA; Zaki MEA
Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558921
[TBL] [Abstract][Full Text] [Related]
2. New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity.
Farzaneh S; Zeinalzadeh E; Daraei B; Shahhosseini S; Zarghi A
Anticancer Agents Med Chem; 2018; 18(2):295-301. PubMed ID: 28971779
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, Molecular Docking and Anticancer Activity of Diflunisal Derivatives as Cyclooxygenase Enzyme Inhibitors.
Coşkun GP; Djikic T; Hayal TB; Türkel N; Yelekçi K; Şahin F; Küçükgüzel ŞG
Molecules; 2018 Aug; 23(8):. PubMed ID: 30082676
[TBL] [Abstract][Full Text] [Related]
4. Novel Phenolic Compounds as Potential Dual EGFR and COX-2 Inhibitors: Design, Semisynthesis, in vitro Biological Evaluation and in silico Insights.
Abdelgawad MA; Musa A; Almalki AH; Alzarea SI; Mostafa EM; Hegazy MM; Mostafa-Hedeab G; Ghoneim MM; Parambi DGT; Bakr RB; Al-Muaikel NS; Alanazi AS; Alharbi M; Ahmad W; Bukhari SNA; Al-Sanea MM
Drug Des Devel Ther; 2021; 15():2325-2337. PubMed ID: 34103896
[TBL] [Abstract][Full Text] [Related]
5. A New Series of Triazolothiadiazines as Potential Anticancer Agents for Targeted Therapy of Non-Small Cell Lung and Colorectal Cancers: Design, Synthesis, In silico and In vitro Studies Providing Mechanistic Insight into Their Anticancer Potencies.
Sever B; Altıntop MD; Çiftçi GA; Özdemir A
Med Chem; 2021; 17(10):1104-1128. PubMed ID: 33087032
[TBL] [Abstract][Full Text] [Related]
6. Novel 1,3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: Design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2.
Shaker AMM; Shahin MI; AboulMagd AM; Abdel Aleem SA; Abdel-Rahman HM; Abou El Ella DA
Bioorg Chem; 2022 Dec; 129():106143. PubMed ID: 36191430
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities.
Ahmed AHH; Mohamed MFA; Allam RM; Nafady A; Mohamed SK; Gouda AE; Beshr EAM
Bioorg Chem; 2022 Dec; 129():106171. PubMed ID: 36166898
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel diphenylthiazole-based cyclooxygenase inhibitors as potential anticancer agents.
Abdelazeem AH; Gouda AM; Omar HA; Tolba MF
Bioorg Chem; 2014 Dec; 57():132-141. PubMed ID: 25462989
[TBL] [Abstract][Full Text] [Related]
9. Discovery of small molecule acting as multitarget inhibitor of colorectal cancer by simultaneous blocking of the key COX-2, 5-LOX and PIM-1 kinase enzymes.
El-Miligy MMM; Al-Kubeisi AK; El-Zemity SR; Nassra RA; Abu-Serie MM; Hazzaa AA
Bioorg Chem; 2021 Oct; 115():105171. PubMed ID: 34303896
[TBL] [Abstract][Full Text] [Related]
10. Selective COX-2 inhibitors as anticancer agents: a patent review (2014-2018).
Mahboubi Rabbani SMI; Zarghi A
Expert Opin Ther Pat; 2019 Jun; 29(6):407-427. PubMed ID: 31132889
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, molecular docking and evaluation of novel sulfonyl hydrazones as anticancer agents and COX-2 inhibitors.
Şenkardeş S; Han Mİ; Kulabaş N; Abbak M; Çevik Ö; Küçükgüzel İ; Küçükgüzel ŞG
Mol Divers; 2020 Aug; 24(3):673-689. PubMed ID: 31302853
[TBL] [Abstract][Full Text] [Related]
12. Novel quinoxaline derivatives as dual EGFR and COX-2 inhibitors: synthesis, molecular docking and biological evaluation as potential anticancer and anti-inflammatory agents.
Ahmed EA; Mohamed MFA; Omran OA
RSC Adv; 2022 Sep; 12(39):25204-25216. PubMed ID: 36199335
[TBL] [Abstract][Full Text] [Related]
13. EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones.
Musa A; Mostafa EM; Bukhari SNA; Alotaibi NH; El-Ghorab AH; Farouk A; Nayl AA; Ghoneim MM; Abdelgawad MA
Molecules; 2022 Feb; 27(4):. PubMed ID: 35208952
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel indanone containing spiroisoxazoline derivatives with selective COX-2 inhibition as anticancer agents.
Abolhasani H; Zarghi A; Komeili Movahhed T; Abolhasani A; Daraei B; Dastmalchi S
Bioorg Med Chem; 2021 Feb; 32():115960. PubMed ID: 33477020
[TBL] [Abstract][Full Text] [Related]
15. Pyrrolizines: Design, synthesis, anticancer evaluation and investigation of the potential mechanism of action.
Gouda AM; Abdelazeem AH; Omar HA; Abdalla AN; Abourehab MAS; Ali HI
Bioorg Med Chem; 2017 Oct; 25(20):5637-5651. PubMed ID: 28916158
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of benzimidazole analogs endowed with oxadiazole as selective COX-2 inhibitor.
Rathore A; Rahman MU; Siddiqui AA; Ali A; Shaharyar M
Arch Pharm (Weinheim); 2014 Dec; 347(12):923-35. PubMed ID: 25303727
[TBL] [Abstract][Full Text] [Related]
17. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
El-Sayed NA; Nour MS; Salem MA; Arafa RK
Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
[TBL] [Abstract][Full Text] [Related]
18. Novel diphenylthiazole derivatives with multi-target mechanism: Synthesis, docking study, anticancer and anti-inflammatory activities.
Abdelazeem AH; El-Saadi MT; Said EG; Youssif BGM; Omar HA; El-Moghazy SM
Bioorg Chem; 2017 Dec; 75():127-138. PubMed ID: 28938224
[TBL] [Abstract][Full Text] [Related]
19. Chemical Characterization,
Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
[TBL] [Abstract][Full Text] [Related]
20. New pyrimidines and triazolopyrimidines as antiproliferative and antioxidants with cyclooxygenase-1/2 inhibitory potential.
Omar AM; Abd El Razik HA; Hazzaa AA; El-Attar MA; El Demellawy MA; Abdel Wahab AE; El Hawash SA
Future Med Chem; 2019 Jul; 11(13):1583-1603. PubMed ID: 31469327
[No Abstract] [Full Text] [Related]
[Next] [New Search]
